Pick of the Week: Abbott India Ltd

Equity Bottom-Up

129 Views, 11 Jan 2022 17:07

EXECUTIVE SUMMARY

Revenue growth of Abbott India Ltd (AIL) for FY21 has outpaced the Indian Pharma Market (IPM) growth by 100 bps majorily contributed by addition of new products
AIL has leadership position in 9 top brands out of 10 in their respective therapies
We recommend BUY with a TP of Rs 20,000/share.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

detail (1-minute read)

WHAT’S TRENDING

Insights